Lawmakers from both parties have expressed their dislike for an entity that could take away their spending authority. But a leading Democrat also raised the fact that the new HHS Secretary, Tom Price, MD, would be harsh on the most vulnerable.
In a blog post Monday, Pharmaceutical Research and Manufacturers of America (PhRMA), took aim at a longtime target: the Independent Payment Advisory Board (IPAB), which was created under the Affordable Care Act (ACA) to rein in spending without reducing quality.
To be sure, IPAB attracts daggers from across the political spectrum—both Senators John Corwyn, R-Texas, and Ron Wyden, D-Oregon, have it in their crosshairs, even though the mechanics of IPAB are such that it has never been activated. But the idea of an executive agency taking away spending power has long rankled the GOP, which Roll Call reported cut funding from the group by $55 million over 4 years.
Under the ACA, the use of IPAB to make Medicare cuts only kicks in if spending rises by a certain target and if Congress fails to act on its recommendations.
PhRMA’s Nicole Longo wrote that the growth target could be met in 2017, which would set IPAB’s process in motion. It’s supposed to consist of 15 experts appointed by the president. But, as Longo wrote, “If no board is appointed, these powers transfer automatically to the Secretary of Health and Human Services,” an office just assumed by Tom Price, MD, an orthopedic surgeon who spent years as a Georgia Congressman fighting the ACA. Instead of checks and balances, Longo wrote the IPAB “is structured to be virtually exempt from such oversight.”
The blog post, and a letter PhRMA released signed by 650 healthcare group, argues that IPAB’s design gives it too much power, and it would be worst still if the power to make cuts fell to the HHS Secretary. “This places an enormous degree of power in the hands of one unelected individual,” the letter stated.
The American Medical Association says on its website it opposes IPAB for similar reasons.
Wyden’s recent statement against IPAB has a twist, however. He writes that Price and others appointed by President Donald Trump “have long records of supporting policies that would shift costs to seniors and other vulnerable Americans.”
Concern about IPAB grew after last year’s report from Medicare’s trustees said that while growth for 2016 had not exceeded targets in the ACA, that might not be the case in 2017. An outline published by the Kaiser Family Foundation projected that if the HHS actuary announces that targets are reached this April, recommendations would be due by September 1, 2017. Congressional committees would have until April 2018 to act. If they do nothing, the HHS secretary could move ahead with cuts by October 1, 2018, to take effect January 1, 2019.
AI in Health Care: Closing the Revenue Cycle Gap
April 1st 2025This commentary explores the current state, challenges, and potential of artificial intelligence (AI) in health care revenue cycle management, emphasizing collaboration, data standardization, and targeted implementation to enhance adoption.
Read More
Varied Access: The Pharmacogenetic Testing Coverage Divide
February 18th 2025On this episode of Managed Care Cast, we speak with the author of a study published in the February 2025 issue of The American Journal of Managed Care® to uncover significant differences in coverage decisions for pharmacogenetic tests across major US health insurers.
Listen
Managed Care Reflections: A Q&A With Hoangmai H. Pham, MD, MPH
April 1st 2025To mark the 30th anniversary of The American Journal of Managed Care® (AJMC®), each issue in 2025 will include a special feature: reflections from a thought leader on what has changed—and what has not—over the past 3 decades and what’s next for managed care. The April issue features a conversation with Hoangmai H. Pham, MD, MPH, a member of AJMC’s editorial board and the president and CEO of the Institute for Exceptional Care (IEC).
Read More
Bridging Care Gaps With a Systemwide Value-Based Care Strategy
March 29th 2025Mapping care management needs by defining patient populations and then stratifying them according to risk and their needs can help to spur the transformation of a siloed health care system into an integrated system that is able to better provide holistic, value-based care despite the many transitions that continue among hospital, primary, specialty, and community care environments.
Read More